THE ARISING · Longevity & Healthspan
Beam's Base-Edited Sickle Cell Therapy Meets Main Goal, FDA Filing Planned
Beam says its investigational base-edited cell therapy met the primary endpoint in a pivotal Phase 1/2 trial. The company plans an FDA submission as early as the end of 2026.
Beam Therapeutics said Tuesday that its treatment, ristoglogene autogetemcel, or risto-cel, met the main goal of its pivotal trial: freedom from severe vaso-occlusive crises. These are the painful episodes that sickle cell disease causes. According to the company, the treatment also met secondary goals, including freedom from inpatient hospitalization for severe crises for at least 12 consecutive months. As of October 20, 49 participants had been treated, and 31 had completed the required follow-up for the primary endpoint.
The approach is called base editing. It can change individual DNA letters precisely and, unlike older CRISPR methods, does not make double-stranded DNA breaks. Doctors take a patient's own cells and re-engineer them to switch on production of fetal hemoglobin, a special oxygen-carrying protein. The cells go back into the patient, settle in the bone marrow and start making normal blood cells. The aim is to stop sickle-shaped cells from forming and causing crises.
Beam says the planned filing could be the first biologics license application for a base-editing therapy. The trial is open-label and single-arm, and the announcement does not provide the detailed pivotal response rate.
Treatment requires collection of the patient’s own blood-forming stem cells, editing outside the body, and a transplant procedure with myeloablative busulfan conditioning. The company said safety findings were consistent with the known risks of these procedures and the underlying disease.
Next to watch are the detailed pivotal results, planned for a medical meeting in 2027, and whether Beam submits its FDA application as early as year-end 2026.